CONTEXT: Concern exists that androgen treatment might adversely impact prostate health in older men. Dihydrotestosterone (DHT), derived from local conversion of testosterone to DHT by 5α-reductase enzymes, is the principal androgen within the prostate. Exogenous androgens raise serum DHT concentrations, but their effects on the prostate are not clear. OBJECTIVE: To determine the impact of large increases in serum DHT concentrations on intraprostatic androgen concentrations and androgen action within the prostate. DESIGN: Double-blind, randomized, placebo-controlled. SETTING: Single academic medical center. PARTICIPANTS: 31 healthy men ages 35-55. INTERVENTION: Daily transdermal DHT or placebo gel. MAIN OUTCOME MEASURES: Serum and prostate tissue androgen concentrations and prostate epithelial cell gene expression after 4 wk of treatment. RESULTS:Twenty-seven men completed all study procedures. Serum DHT levels increased nearly sevenfold, while testosterone levels decreased in men treated with daily transdermal DHT gel but were unchanged in the placebo-treated group (P < 0.01 between groups). In contrast, intraprostatic DHT and testosterone concentrations on d 28 were not different between groups (DHT: placebo = 2.8 ± 0.2 vs. DHT gel = 3.1 ± 0.5 ng/g; T: placebo = 0.6 ± 0.2 vs. DHT gel = 0.4 ± 0.1, mean ± se). Similarly, prostate volume, prostate-specific antigen, epithelial cell proliferation, and androgen-regulated gene expression were not different between groups. CONCLUSIONS: Robust supraphysiologic increases in serum DHT, associated with decreased serum T, do not significantly alter intraprostatic levels of DHT, testosterone, or prostate epithelial cell androgen-regulated gene expression in healthy men. Changes in circulating androgen concentrations are not necessarily mimicked within the prostate microenvironment, a finding with implications for understanding the impact of androgen therapies in men.
RCT Entities:
CONTEXT: Concern exists that androgen treatment might adversely impact prostate health in older men. Dihydrotestosterone (DHT), derived from local conversion of testosterone to DHT by 5α-reductase enzymes, is the principal androgen within the prostate. Exogenous androgens raise serum DHT concentrations, but their effects on the prostate are not clear. OBJECTIVE: To determine the impact of large increases in serum DHT concentrations on intraprostatic androgen concentrations and androgen action within the prostate. DESIGN: Double-blind, randomized, placebo-controlled. SETTING: Single academic medical center. PARTICIPANTS: 31 healthy men ages 35-55. INTERVENTION: Daily transdermal DHT or placebo gel. MAIN OUTCOME MEASURES: Serum and prostate tissue androgen concentrations and prostate epithelial cell gene expression after 4 wk of treatment. RESULTS: Twenty-seven men completed all study procedures. Serum DHT levels increased nearly sevenfold, while testosterone levels decreased in men treated with daily transdermal DHT gel but were unchanged in the placebo-treated group (P < 0.01 between groups). In contrast, intraprostatic DHT and testosterone concentrations on d 28 were not different between groups (DHT: placebo = 2.8 ± 0.2 vs. DHT gel = 3.1 ± 0.5 ng/g; T: placebo = 0.6 ± 0.2 vs. DHT gel = 0.4 ± 0.1, mean ± se). Similarly, prostate volume, prostate-specific antigen, epithelial cell proliferation, and androgen-regulated gene expression were not different between groups. CONCLUSIONS: Robust supraphysiologic increases in serum DHT, associated with decreased serum T, do not significantly alter intraprostatic levels of DHT, testosterone, or prostate epithelial cell androgen-regulated gene expression in healthy men. Changes in circulating androgen concentrations are not necessarily mimicked within the prostate microenvironment, a finding with implications for understanding the impact of androgen therapies in men.
Authors: Gerald L Andriole; David G Bostwick; Otis W Brawley; Leonard G Gomella; Michael Marberger; Francesco Montorsi; Curtis A Pettaway; Teuvo L Tammela; Claudio Teloken; Donald J Tindall; Matthew C Somerville; Timothy H Wilson; Ivy L Fowler; Roger S Rittmaster Journal: N Engl J Med Date: 2010-04-01 Impact factor: 91.245
Authors: M Y Roth; S T Page; K Lin; B D Anawalt; A M Matsumoto; C N Snyder; B T Marck; W J Bremner; J K Amory Journal: J Clin Endocrinol Metab Date: 2010-05-19 Impact factor: 5.958
Authors: Olga M Calof; Atam B Singh; Martin L Lee; Anne M Kenny; Randall J Urban; Joyce L Tenover; Shalender Bhasin Journal: J Gerontol A Biol Sci Med Sci Date: 2005-11 Impact factor: 6.053
Authors: Elahe A Mostaghel; Linda Geng; Ilona Holcomb; Ilsa M Coleman; Jared Lucas; Lawrence D True; Peter S Nelson Journal: Cancer Res Date: 2010-02-02 Impact factor: 12.701
Authors: Sherri-Ann M Burnett-Bowie; Elizabeth A McKay; Hang Lee; Benjamin Z Leder Journal: J Clin Endocrinol Metab Date: 2009-10-09 Impact factor: 5.958
Authors: Jennifer D Wu; Daniel W Lin; Stephanie T Page; Ashley D Lundgren; Lawrence D True; Stephen R Plymate Journal: Transl Oncol Date: 2009-03 Impact factor: 4.243
Authors: Hung-Ming Lam; Holly M Nguyen; Mark P Labrecque; Lisha G Brown; Ilsa M Coleman; Roman Gulati; Bryce Lakely; Daniel Sondheim; Payel Chatterjee; Brett T Marck; Alvin M Matsumoto; Elahe A Mostaghel; Michael T Schweizer; Peter S Nelson; Eva Corey Journal: Eur Urol Date: 2019-06-19 Impact factor: 20.096
Authors: Ronald S Swerdloff; Robert E Dudley; Stephanie T Page; Christina Wang; Wael A Salameh Journal: Endocr Rev Date: 2017-06-01 Impact factor: 19.871
Authors: Jamie M Sperger; Lindsay N Strotman; Allison Welsh; Benjamin P Casavant; Zachery Chalmers; Sacha Horn; Erika Heninger; Stephanie M Thiede; Jacob Tokar; Benjamin K Gibbs; David J Guckenberger; Lakeesha Carmichael; Scott M Dehm; Philip J Stephens; David J Beebe; Scott M Berry; Joshua M Lang Journal: Clin Cancer Res Date: 2016-07-11 Impact factor: 12.531
Authors: Mary-Ellen Taplin; Bruce Montgomery; Christopher J Logothetis; Glenn J Bubley; Jerome P Richie; Bruce L Dalkin; Martin G Sanda; John W Davis; Massimo Loda; Lawrence D True; Patricia Troncoso; Huihui Ye; Rosina T Lis; Brett T Marck; Alvin M Matsumoto; Steven P Balk; Elahe A Mostaghel; Trevor M Penning; Peter S Nelson; Wanling Xie; Zhenyang Jiang; Christopher M Haqq; Daniel Tamae; NamPhuong Tran; Weimin Peng; Thian Kheoh; Arturo Molina; Philip W Kantoff Journal: J Clin Oncol Date: 2014-10-13 Impact factor: 44.544
Authors: Eric G Bluemn; Elysia Sophie Spencer; Brigham Mecham; Ryan R Gordon; Ilsa Coleman; Daniel Lewinshtein; Elahe Mostaghel; Xiaotun Zhang; James Annis; Carla Grandori; Christopher Porter; Peter S Nelson Journal: Mol Cancer Res Date: 2013-03-14 Impact factor: 5.852
Authors: Ye Zhou; Maya Otto-Duessel; Miaoling He; Susan Markel; Tim Synold; Jeremy O Jones Journal: J Mol Endocrinol Date: 2013-06-29 Impact factor: 5.098